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Background: Activation of the sodium-hydrogen ion exchange mechanism results in
accumulation of intracellular calcium through the sodium-calcium ion antiport
mechanism. Administration of a sodium-hydrogen ion exchange inhibitor before or
during ischemia attenuates myocardial ischemia and reperfusion injury. However,
the cardioprotection exerted by sodium-hydrogen ion exchange inhibitors as ad-
juncts to cardioplegia without perioperative administration has not been tested in a
model of surgical reperfusion of acute coronary occlusion with cardiopulmonary
bypass. This study tested the hypothesis that sodium-hydrogen ion exchange inhibi-
tor–supplemented blood cardioplegia would reduce postcardioplegia injury after
severe regional ischemia.
Methods: In anesthetized open-chest dogs, the left anterior descending coronary
artery was occluded for 75 minutes, after which total cardiopulmonary bypass was
initiated. After crossclamping, cold (4°C) antegrade blood cardioplegia was deliv-
ered every 20 minutes for a total of 60 minutes of cardioplegic arrest. In 8 dogs, the
blood cardioplegic solution was unsupplemented (vehicle group), whereas in 8
others the solution was supplemented with the sodium-hydrogen ion exchange
inhibitor cariporide (10 mol/L, cariporide group).
Results: In the in vitro studies, the direct effects of cariporide on neutrophil function
were determined. Isolated canine neutrophils were stimulated by platelet activating
factor. Cariporide attenuated superoxide anion production in a concentration-depen-
dent manner, with no appreciable effect at 10 mol/L (the concentration used in
blood cardioplegia) and a peak effect at 100 mol/L. In the in vivo cardiopulmonary
bypass model, infarct size was significantly (P  .05) smaller in the cariporide
group than in the vehicle group (22.4%  3.5% vs 40.1%  5.1% of area at risk),
although there were no group differences in postischemic regional wall motion after
2 hours of reperfusion (0.1%  0.9% vs 0.2%  0.3% systolic shortening).
Transmural myocardial edema in the area at risk was significantly decreased in the
cariporide group (80.6%  0.5%) relative to the vehicle group (83.1%  0.6%).
Myeloperoxidase activity in the area at risk, an index of neutrophil accumulation,
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was significantly lower in the cariporide group than in the vehicle group (4.7  0.9
absorbence units/[min  g tissue] vs 10.3  2.3 absorbence units/[min  g tissue]). In
isolated postischemic left anterior descending coronary artery rings, maximum
relaxation in response to the endothelium-dependent vasodilator acetylcholine was
significantly greater in the cariporide group than in the vehicle group (77.5% 
7.4% vs 51.4%  8.0%), whereas smooth muscle relaxation in response to nitro-
prusside was comparable between groups.
Conclusion: In this canine model, supplementation of blood cardioplegia with
cariporide, a sodium-hydrogen ion exchange inhibitor, reduced infarct size, atten-
uated neutrophil accumulation in the area at risk, and reduced postischemic coronary
artery endothelial dysfunction without directly inhibiting neutrophil activity. Cari-
poride as an adjunct to blood cardioplegia without perioperative administration
attenuated surgical ischemia-reperfusion injury in jeopardized myocardium.
Cardiac surgery is performed on hundreds ofthousands of patients each year to alleviatecoronary artery disease, valve problems,and other cardiac diseases. Although theoperative outcomes with current formula-tions of cardioplegic solutions are gener-
ally acceptable, with low morbidity and mortality, patients
at high risk, such as those with an evolving myocardial
infarction, low ejection fraction, or cardiogenic shock, re-
quire additional strategies to adequately protect the vulner-
able myocardium during cardiac surgery. Current strategies
in on-pump myocardial protection advocate the use of car-
dioplegic solutions not only to arrest the heart but to act as
a vector by which to introduce cardioprotective agents tar-
geting specific mechanisms of ischemia-reperfusion injury.
Activation of the Na-H exchanger (NHE) has been
implicated in the pathogenesis of tissue ischemia-reperfu-
sion injury.1-3 Under normal conditions, the Na-H anti-
port mechanism operates in the forward direction, driven by
the inwardly directed transmembrane sodium ion gradient
and expelling a single intracellular hydrogen ion in ex-
change, thereby maintaining intracellular pH and regulating
intracellular sodium level.4 During ischemia, however, the
accumulation of intracellular hydrogen provides the greater
driving force for the antiporter, with a resulting efflux of
hydrogen ion to the extracellular compartment and a net
intracellular accumulation of sodium. The robust buildup of
protons in the extracellular compartment during ischemia
eventually reduces the transmembrane gradient, which in
turn may inhibit NHE activity and increase sodium accu-
mulation. At reperfusion, however, washout of protons in
the extracellular compartment restores a transmembrane
gradient favoring proton efflux. Thus the antiporter be-
comes reactivated during reperfusion,5 with a resulting net
influx and accumulation of intracellular sodium. The con-
sequent accumulation in intracellular sodium stimulates cal-
cium ion influx through the Na-Ca2 antiporter and accu-
mulation of intracellular free calcium. Intracellular calcium
ion accumulation has been implicated in the pathogenesis of
systolic and diastolic dysfunction and in the transition to
irreversible tissue injury after ischemia and reperfusion.6,7
Accordingly, inhibition of the NHE mechanism has been
advocated as a cardioprotective strategy.8-10 Previous stud-
ies have consistently demonstrated that inhibition of the
NHE mechanism results in decreased accumulation of in-
tracellular sodium4 and subsequently decreased calcium
overload and myocardial damage during nonsurgical isch-
emia and reperfusion when administered before the isch-
emic event.1,9,11 Indeed, the cardioprotection during coro-
nary occlusion and reperfusion observed with NHE
inhibition rivals that observed with ischemic precondition-
ing, and it may in fact be synergistic with preconditioning or
may exceed the cardioprotection observed with precondi-
tioning.12 However, whether cardioprotection is exerted
when the NHE inhibitor is administered at reperfusion re-
mains controversial.13-15
In cardiac surgery under cardiopulmonary bypass (CPB)
and intermittent cardioplegia, potential injury may occur
during intraoperative ischemia between multidose infusions
of cardioplegic solution or as a result of maldistribution of
solution distal to total coronary occlusions. This intraoper-
ative injury may be additive to the antecedent injury caused
by regional ischemia, heart failure, cardiogenic shock, and
so on. In addition, there is potential for reperfusion injury
during each infusion of cardioplegic solution and after re-
moval of the aortic crossclamp. Neutrophils play an impor-
tant role in the pathogenesis of ischemia-reperfusion inju-
ry,16 particularly in cardiac surgery, where the
extracorporeal circuitry amplifies the inflammatory re-
sponse.17
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Several studies performed in isolated perfused-heart
preparations have indicated that inclusion of amiloride an-
alogs or other NHE inhibitors attenuates postischemic or
postcardioplegia contractile dysfunction.18,19 Moreover, in a
clinical randomized trial (the GUARDIAN trial20) the se-
lective NHE type 1 isoform (NHE-1) inhibitor cariporide
(HOE 642) was administered intravenously during the peri-
operative period to high-risk patients who underwent coro-
nary artery bypass grafting. This study reported a significant
reduction in combined infarction and mortality. However,
few reports have tested the cardioprotective effects of NHE
inhibitors with in vivo models of surgical revascularization
in which neutrophils may participate in the inflammatory
component of reperfusion injury. Neither have any studies
to date tested the potential benefits of NHE inhibitors as an
adjunct to blood cardioplegia in vivo. Accordingly, this
study tested the hypothesis that the selective NHE inhibitor
cariporide would attenuate postcardioplegia injury when
given as an additive to blood cardioplegic solution in a
canine model simulating on-pump surgical revasculariza-
tion of evolving myocardial infarction.
Material and Methods
Experimental Preparation
All animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press, revised
1996.
In vitro superoxide anion generation by activated neutrophils.
Experiments were performed to determine the direct effects of
cariporide or neutrophil function. To isolate neutrophils, peripheral
canine blood (200 mL) was mixed with 45 mL of anticoagulating
agents, which included 1.6% citric acid and 2.5% sodium citrate
(pH 5.4), and 100 mL of 6% dextran solution in buffered Hanks
balanced salt solution. Polymorphonuclear neutrophils were iso-
lated with the Ficoll-Pacque (Sigma Chemical, St Louis, Mo)
technique described in detail elsewhere.21 The cells were adjusted
to approximately 9  107 cells/mL. Final suspensions contained
94%  1% neutrophils, and cell viability averaged 99%  0.5%,
as determined by trypan blue exclusion. Superoxide anion produc-
tion by neutrophils stimulated by platelet activating factor (100
nmol) were determined by measuring the superoxide dismutase-
inhibitable reduction of ferricytochrome C to ferrocytochrome C
spectrophotometrically at 550 nm with a V-Max Microtiter Plate
Reader (Molecular Devices Corporation, Sunnyvale, Calif). In
addition, degranulation of platelet-activating factor–stimulated
neutrophils was determined by analysis of myeloperoxidase activ-
ity.
In vivo study. Twenty healthy mongrel dogs of either sex
weighing 22.4 to 31.6 kg (average weight 27.4  1.0 kg) were
initially anesthetized by intravenous administration of 2.5% thio-
pental (20 mg/kg) followed by constant infusion of fentanyl citrate
(0.4 g/[kg  min]) and diazepam (0.003 mg/[kg  min]) during the
experiment. Each dog was endotracheally intubated and mechan-
ically ventilated to maintain Pao2 at greater than 100 mm Hg,
Paco2 between 35 and 45 mm Hg, and pH between 7.35 and 7.45.
Metabolic acidemia was corrected with sodium bicarbonate infu-
sion as needed. Polyethylene catheters were inserted into the
femoral artery for arterial blood sampling and for monitoring
systemic arterial blood pressure, and a catheter was inserted into
the femoral vein for fluid administration. A rectal temperature
probe was inserted to measure core body temperature. After me-
dian sternotomy, the superior and inferior venae cavae were
loosely encircled with umbilical tapes, the azygos vein was ligated,
and the heart was suspended in a pericardial cradle. Millar cathe-
ter-tipped pressure transducers (model MPC-500; Millar Instru-
ments, Inc, Houston, Tex) were placed into the proximal aorta
through the right internal thoracic artery and into the left ventric-
ular cavity through an apical stab incision. A 1-cm portion of the
left anterior descending coronary artery (LAD) distal to the first
diagonal branch was dissected and loosely encircled with a 2-0 silk
suture, which was later used to produce regional myocardial isch-
emia. A pair of 5-MHz piezoelectric ultrasonic crystals, 2.5 to 3.0
mm in diameter, was placed in the subendocardium of the myo-
cardium perfused by the LAD (ischemic-reperfused segment) to
measure instantaneous segmental dimensions with a sonomi-
crometer (model 120; Triton Technology, Inc, San Diego, Calif).
The dogs were systemically anticoagulated with sodium hepa-
rin at 300 U/kg, supplemented every 90 minutes with an additional
150 U/kg to maintain the activated clotting time at more than 400
seconds. The left subclavian artery was cannulated for aortic
perfusion, and the superior and inferior vena caval cannulas were
inserted through the right atrium for venous return. The cannula
tips were kept in the atrium until the institution of CPB to avoid
hemodynamic interference. A double-lumen cardioplegic catheter
(Medtronic DLP, Grand Rapids, Mich) was inserted into the as-
cending aorta proximal to the aortic crossclamp for the simulta-
neous delivery of blood cardioplegia and measurement of car-
dioplegic infusion pressure. Venous blood was oxygenated with a
membrane oxygenator (COBE Cardiovascular, Inc, Arvada, Colo)
and passed through a 50-m filter and bubble trap before it was
returned to the arterial circulation. The rate of oxygenation was
adjusted to maintain the systemic Pao2 at greater than 200 mm Hg
and the Paco2 between 30 and 40 mm Hg. Metabolic acidosis was
counteracted with sodium bicarbonate to maintain arterial blood
pH between 7.35 and 7.45. The mean arterial blood pressure
during CPB was maintained at 70 mm Hg by adjustment of the
blood flow through the arterial cannula. A myocardial temperature
probe was placed in the anterior wall of the left ventricle.
Experimental Protocol
After all surgical instrument placement, hemodynamic data and
blood samples were obtained at baseline. Each dog then received
a bolus injection of lidocaine (1.2 mg/kg) followed by a continuous
infusion (0.3 mg/[kg  min]), after which the LAD was ligated just
distal to the first diagonal branch for 75 minutes. After 75 minutes
of LAD regional ischemia, the cannulas were advanced and CPB
was initiated. The left ventricle was vented by gravity drainage
through a transmyocardial cannula, and the systemic blood tem-
perature was reduced to 28°C. The dogs were randomly allocated
into groups that received blood cardioplegia supplemented with
either saline vehicle (vehicle group, n  8) or 10 mol/L of HOE
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642 (cariporide group, n  8) at equivalent volumes of diluent.
The aorta was crossclamped, and cardioplegic arrest was induced
with multidose, hypothermic, hyperkalemic blood cardioplegic
solution (66 parts blood to 1 part crystalloid) of the following
composition: 20.0-mEq/L (induction, terminal) or 10.0-mEq/L (in-
termittent) potassium ion, 1.0 mmol/L calcium ion, and 0.4-
mmol/L magnesium ion, at pH 7.4 with tris(hydroxymethyl)ami-
nomethane. The blood cardioplegic solution was delivered with the
Myocardial Protection System cardioplegia and perfusion system
(Quest Medical, Dallas, Tex). High-potassium blood cardioplegia
(20-mEq/L potassium ion, 4°C) was delivered for 3 minutes during
induction, and low-potassium blood cardioplegia (approximately
10-mEq/L potassium ion) was delivered for 2 minutes after 20 and
40 minutes of arrest at an aortic root pressure of 50 mm Hg. The
LAD ligature was loosened before the second cardioplegic infu-
sion to simulate revascularization of a target vessel. After 60
minutes of cardioplegic arrest, a hot-shot (20-mEq/L potassium
ion, 27°C) infusion of blood cardioplegia was delivered for 3
minutes. Systemic blood was rewarmed to 37°C by the end of the
hour of cardioplegic arrest, and the aorta was unclamped to initiate
reperfusion. After cardiac electromechanical activity appeared, the
mean arterial pressure was gradually increased from 50 to 80 mm
Hg through a period of 5 minutes. The heart was maintained on
total vented bypass for the first 30 minutes of reperfusion (beating
empty reperfusion). Subsequently, all hearts were weaned from
CPB and reperfusion was continued in the working state for an
additional 90 minutes. The experiment was terminated with a bolus
of intravenous sodium pentobarbital (100 mg/kg). The heart was
immediately excised and placed in cold Krebs-Henseleit solution
oxygenated with 95% oxygen and 5% carbon dioxide and with the
following composition: 118.1-mmol/L sodium chloride, 4.7-
mmol/L potassium chloride, 1.2-mmol/L monobasic potassium
phosphate, 1.2-mmol/L magnesium sulfate, 2.5-mmol/L calcium
chloride dihydrate, 25.0-mmol/L sodium hydrogen carbonate, and
11.1-mmol/L glucose at pH 7.4.
Data collection and analysis. Hemodynamic and segmental
length data were acquired during a 10-second period of respiratory
apnea. The data from each channel were digitized and processed
by computer algorithms with an interactive videographics program
(SPECTRUM; Wake Forest University, Winston-Salem, NC) as
described previously elsewhere.22 Percentage segmental short-
ening and segmental stroke work were determined as described
previously elsewhere.22 Measurements were taken before LAD
occlusion (baseline), after 75 minutes of LAD occlusion, after
30 minutes of empty beating reperfusion, and every 30 minutes
during the 90 minutes of reperfusion in the off-pump working
state.
Determination of area at risk and infarct size. After postex-
perimental excision of the heart, a catheter was inserted into the
aortic root. The LAD ligature was retied, and Unisperse blue
pigment (Ciba Specialty Chemicals Company, High Point, NC)
was injected under a perfusion pressure of 100 mm Hg to stain the
normally perfused region blue and thereby demarcate the area at
risk. The left ventricle was cut into 4- to 5-mm thick transverse
slices. The area at risk was separated from the nonischemic zone
and incubated for 15 minutes in 1% triphenyltetrazolium chloride
(Sigma, St Louis, Mo) at 37°C to differentiate the necrotic zone
(pale) from the ischemic nonnecrotic zone (red). The area at risk
was calculated as the sum of the weights of the nonnecrotic and
necrotic tissues within the ischemic zone, divided by the weight of
the left ventricle and expressed as a percentage (area at risk
percentage). The infarct size was calculated as the weight of
necrotic tissue divided by the weight of the area at risk and
expressed as a percentage (infarct percentage).
Plasma creatine kinase activity. Arterial blood samples (3
mL) were centrifuged at 2500g and 4°C for 10 minutes. The
plasma was drawn off and analyzed spectrophotometrically for
creatine kinase (CK) activity and for protein concentration (CK-10
kit; Sigma Diagnostics, St Louis, Mo). Plasma CK activity was
expressed in international units per gram of protein.
Determination of myocardial edema. Postexperimental trans-
mural myocardial tissue samples were taken from the nonischemic
zone and from the area at risk. Each sample was further subdivided
into subepicardial and subendocardial regions, blotted to remove
surface moisture, weighed, and desiccated for 48 hours. Percentage
myocardial water content was determined as follows: ([wet
weight  dry weight]/wet weight)  100%.
Cardiac myeloperoxidase activity. Postexperimental transmu-
ral myocardial tissue samples were taken from the nonischemic
zone and from the nonnecrotic and necrotic areas of the area at risk
for spectrophotometric analysis of myeloperoxidase activity as an
assessment of neutrophil accumulation in myocardium, as de-
scribed previously elsewhere.23 MPO activity was expressed as the
change in absorbence units per minute per gram of myocardial
tissue.
Postexperimental coronary artery endothelial function. Both
the ischemic-reperfused LAD and nonischemic left circumflex
coronary artery (LCx) were carefully dissected from the heart, and
endothelial function was quantified by relaxation responses to
incremental concentrations of the endothelium-specific nitric oxide
synthase stimulator acetylcholine in organ chambers, as described
previously elsewhere.24 The vascular rings were placed at the
optimal point of their length-tension relationship and incubated
with 10-mol/L indomethacin to prevent vascular responses to
endogenous prostacyclin. The coronary rings were then contracted
with 10 nmol/L of the thromboxane A2 mimetic agent U46619
(Pharmacia & Upjohn, Bridgewater, NJ). The procedure was re-
peated for sodium nitroprusside (Sigma) to test endothelium-inde-
pendent vascular smooth muscle relaxation. Relaxation was ex-
pressed as a percentage of U46619-induced constriction. Drug
concentrations were expressed as the final concentration in the
organ chamber.
Statistical Analysis
The data were analyzed by 1-way or 2-way analysis of variance for
repeated measures to identify group, time, and group-time inter-
actions. If significant interactions were found, then further pair-
wise analysis was performed by post hoc analysis to locate the
source of differences. Comparisons between the two groups in the
area at risk, infarct size, MPO activity, myocardial edema, and
percentage relaxation of postischemic coronary artery rings at each
concentration were analyzed with the Student t test. Data are
reported as mean  SEM.
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Results
In Vitro Effect of Cariporide on Neutrophil
Superoxide Generation and Degranulation
The effects of cariporide on degranulation and superoxide
generation in neutrophils stimulated with platelet-activating
factor are summarized in Table 1. Platelet-activating factor
significantly increased the superoxide anion generation rel-
ative to control, unstimulated neutrophils. There was a
general trend toward decreased superoxide anion generation
with increasing concentrations of cariporide. However, a
significant reduction was observed at cariporide concentra-
tions of 100 mol/L and 200 mol/L. Likewise, cariporide
maximally inhibited degranulation in a concentration-de-
pendent manner, with a significant and maximum effect at
100 mol/L. on the basis of these results, a cariporide
concentration of 10 mol/L was chosen to target cardiopro-
tection of myocytes, rather than the higher concentrations
necessary to inhibit neutrophil function directly. The con-
centration of cariporide used in the cardioplegic solution
thus had no direct effect on neutrophil function.
In Vivo Study
Twenty animals were initially entered into the experimental
phase of the study. Four were excluded because of intrac-
table ventricular fibrillation during the LAD occlusion. The
remaining dogs were equally divided into groups that re-
ceived blood cardioplegia supplemented with either saline
vehicle (vehicle, n 8) or 10-mol/L HOE 642 (cariporide,
n  8) at equivalent volumes of diluent.
Myocardial temperature and cardioplegia variables.
There were no group differences in blood cardioplegia
variables within each time point (Table 2). Anterior myo-
cardial temperatures were not statistically different between
the two groups during the initial, maintenance (20 minutes
and 40 minutes of infusion), or terminal cardioplegia infu-
sions (Table 2).
TABLE 2. Blood cardioplegia variables
Group Initial cold infusion 20-min infusion 40-min infusion Terminal warm infusion
Blood cardioplegia Vehicle 384 17 254 18 299 24 422 30
volume (mL) Cariporide 336 22 277 27 280 19 429 36
Myocardial temperature Vehicle 17.0 1.7 11.8 1.5 11.0 1.3 23.2 3.6
(°C) Cariporide 15.1 2.6 9.7 2.3 9.1 1.4 21.1 2.5
Hematocrit (%) Vehicle 21.6 1.6 20.7 1.6 19.1 1.3 19.9 1.5
Cariporide 21.7 1.7 19.3 1.0 19.6 0.7 18.4 1.0
pH (at 37°C) Vehicle 7.36 0.03 7.37 0.04 7.46 0.03 7.44 0.03
Cariporide 7.34 0.01 7.36 0.01 7.43 0.01 7.42 0.01
Potassium ion (mmol/L) Vehicle 23.6 1.2 13.9 0.3 14.8 0.5 25.4 1.4
Cariporide 20.5 1.6 13.8 0.4 14.5 0.4 24.3 1.8
Calcium ion (mmol/L) Vehicle 0.99 0.06 1.04 0.03 1.06 0.04 1.14 0.07
Cariporide 0.84 0.08 1.03 0.04 1.07 0.04 1.01 0.08
Magnesium ion (mmol/L) Vehicle 0.36 0.04 0.40 0.00 0.40 0.00 0.43 0.02
Cariporide 0.36 0.04 0.37 0.02 0.39 0.01 0.37 0.06
Glucose (mg/dL) Vehicle 139 9 139 10 157 12 162 14
Cariporide 116 6 136 8 142 8 156 10
Osmolality (mOsm/kg) Vehicle 294 2 301 2 300 2 296 2
Cariporide 300 2 302 4 299 1 298 1
There were no significant differences within groups or between groups. There were no differences between groups at any time.
TABLE 1. The effect of increasing concentrations of cariporide on superoxide anion generation (nMol/5  106 PMN) and
degranulation (as a percentage decrease from platelet-activating factor–stimulated degranulation) by neutrophils stimu-
lated by 100-nmol/L platelet activating factor
Cariporide (mol/L) Superoxide anion P value Degranulation (%) P value
Control 3.22 0.55* .0001 -
0 30.33 4.49 0
10 26.06 4.52 .4 6.5 1.8† .001
50 20.60 4.54 .09 12.3 1.7† .0001
100 13.88 2.79* .003 28.9 2.2† .0001
200 7.5 5.4* .003 64.2 1.2† .0001
Control neutrophils were not stimulated with platelet-activating factor.
*P  .05 versus platelet activating factor activated neutrophils (0 concentration cariporide).
†P  .05 versus platelet activating factor-stimulated and untreated group (no cariporide).
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Hemodynamic data. Hemodynamic data during the
course of the experiment are shown in Table 3. There were
no significant differences between the two groups at each
time point in most hemodynamic variables, except that the
heart rate in the vehicle group was significantly greater than
that in the cariporide group at 60 minutes of reperfusion.
Cardiodynamic function. Both groups exhibited com-
parable baseline systolic shortening and systolic dysfunc-
tion in the area at risk during LAD occlusion. Hearts that
received either cariporide-supplemented blood cardioplegia
or unsupplemented blood cardioplegia exhibited poor re-
covery of percentage segmental shortening in the area at
risk throughout reperfusion (Table 4). With segmental
stroke work, there was a strong tendency toward a greater
recovery in the cariporide group at 90 minutes of reperfu-
sion (P  .09) and at 120 minutes of reperfusion (P  .10).
At these time points, the pressure-segment length loops in
the cariporide group were displaced to the left of the base-
line loops and demonstrated systolic bulging. There was an
“opening” of the loop caused by late systolic contraction, so
that positive work was performed. However, the degree of
segment work performed was inconsistent, as evidenced by
the large SEM. Some inconsistency was also observed in the
vehicle group at 90 and 120 minutes of reperfusion.
Area at risk and infarct size. The area placed at risk by
the LAD coronary artery occlusion, expressed as area at risk
percentage (Figure 1), was comparable between the two
groups (31.3%  4.1% and 35.3%  4.0% in the vehicle
and cariporide groups, respectively). Infarct size, expressed
as infarct percentage (Figure 1), was significantly reduced
by nearly half in cariporide-treated hearts (22.4% 0.04%)
relative to the vehicle group (40.1%  0.05%).
Plasma creatine kinase activity. CK activities at base-
line and at the end of 75 minutes of ischemia were compa-
rable between the two groups (Figure 2). There was no
significant increase in CK activity during LAD occlusion in
either group relative to baseline values. Although both
groups showed an increase in plasma CK activity during
reperfusion, there was a significant reduction in CK activity
throughout reperfusion in the cariporide group relative to
the vehicle group (Figure 2). The degree of reduction in CK
activity in the cariporide group was qualitatively similar to
the reduction in infarct size.
Cardiac myeloperoxidase activity. MPO activities in the
nonischemic zone were low and comparable between the
two groups (Figure 3). In both the ischemic nonnecrotic and
necrotic zones, MPO activities were significantly reduced in
the cariporide group relative to the vehicle group, which
TABLE 4. Regional cardiodynamic data in the area at risk during the experiment
Variable Group Baseline Ischemia
Reperfusion
60 min 90 min 120 min
End-diastolic length Vehicle 16.7 1.1 19.9 1.2 18.5 0.9 18.2 0.9 18.3 0.9
(mm) Cariporide 16.4 0.4 20.4 0.7 17.2 0.5 17.1 0.5 17.1 0.5
End-systolic length Vehicle 14.2 1.0 21.0 1.2 18.6 1.1 18.4 1.0 18.3 1.0
(mm) Cariporide 13.9 0.5 20.9 0.7 16.7 0.5 16.7 0.5 16.7 0.5
Percentage segmental Vehicle 15.2 1.3 5.6 1.3 0.1 1.0 0.7 0.7 0.2 0.3
shortening (%) Cariporide 15.0 1.7 5.0 0.8 1.8 0.8 0.8 0.8 0.1 0.9
Segmental stroke Vehicle 184.4 32.9 8.0 4.2 15.2 13.2 1.9 9.5 7.9 4.9
work (mm Hg  mm) Cariporide 156.6 17.6 6.3 3.2 43.7 7.4 22.8 6.2* 25.3 8.5†
There were no significant differences between groups.
*P  .09.
†P  .10.
TABLE 3. Hemodynamic variables during the course of the experiment
Variable Group Baseline Ischemia
Reperfusion
60 min 90 min 120 min
Heart rate Vehicle 103.0 4.6 124.8 4.4 142.2 2.5 138.1 3.0 133.0 2.6
(beats/min) Cariporide 100.5 8.0 114.1 8.9 126.8 4.9* 129.6 4.3 126.0 6.5
Mean arterial Vehicle 82.0 3.4 77.5 3.2 72.1 1.3 64.5 2.2 71.4 3.0
pressure
(mm Hg)
Cariporide 76.5 1.3 78.8 2.3 72.1 3.1 70.0 1.9 75.4 1.3
Left ventricular Vehicle 6.8 0.9 7.9 0.9 8.3 1.2 7.6 1.0 8.3 1.2
end-diastolic
pressure
(mm Hg)
Cariporide 7.2 0.7 8.7 0.6 9.0 0.5 8.6 0.8 8.5 0.7
*P  .05 (P  .01) versus vehicle within the same time point.
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suggests a reduction in neutrophil accumulation in the area
at risk with cariporide-supplemented blood cardioplegia.
Myocardial edema. After 2 hours of reperfusion, the
myocardium in the vehicle group demonstrated the greatest
edema in the area at risk subendocardium, with tissue water
content averaging 84.1%  0.7% (Figure 4). In the caripo-
ride group, there were reductions in myocardial edema in
the subepicardial and subendocardial regions of the area at
risk relative to the vehicle group.
Postexperimental coronary artery endothelial function.
Vasorelaxation responses to acetylcholine and sodium ni-
troprusside in isolated postexperimental coronary artery
rings taken from the ischemic-reperfused LAD and the
nonischemic LCx are summarized in Figure 5. Figure 5, A,
shows the percentages of relaxation with vasodilators in the
vehicle group. The response to acetylcholine, an endotheli-
um-dependent and muscarinic receptor-mediated vasodila-
tor, was significantly (P  .04) blunted in the LAD rings
(maximum 51.4%  8.0% relaxation with the highest con-
centration) relative to the nonoccluded LCx rings (maxi-
mum 79.4%  10.6%). In contrast, the responses to acetyl-
choline in the LAD (maximum 77.5%  7.3%) and LCx
(maximum 85.4%  6.9%) rings were comparable in the
cariporide group (Figure 5, B), with LCx rings in the two
groups relaxing comparably. The endothelium-independent
vasodilator sodium nitroprusside caused comparable relax-
ations in the two groups (Figure 5, A and B), with no
significant difference between the LAD and LCx rings.
These data indicate that cariporide-supplemented cardiople-
gia protected endothelial function from ischemia-reperfu-
sion injury.
Discussion
The Na-H exchange mechanism has been implicated in
the pathogenesis of ischemia-reperfusion injury in the myo-
cardium.1,25 Lethal effects are seen when sodium ion influx
in exchange for hydrogen ion efflux stimulates calcium ion
accumulation through the Na-Ca2 antiporter. Accord-
ingly, NHE inhibitors have been advocated as a cardiopro-
tective strategy during nonsurgical myocardial ischemia and
reperfusion.4,8,10 Previous studies of ischemia-reperfusion
have reported significant reductions in infarct size,14,15,26,27
reduced incidence of arrhythmias,26,28,29 and attenuation of
apoptotic cell death29,30 with NHE inhibitors. In contrast,
the cardioprotective effects afforded by NHE inhibitors
during surgical ischemia and reperfusion have to date been
examined primarily in isolated perfused-heart studies that
used crystalloid cardioplegic solutions, with systolic func-
tion as the major end point.18,31 In this study we investigated
the potential of the NHE inhibitor cariporide (HOE 642) as
an adjunct to blood cardioplegia only to reduce postcar-
dioplegia injury after normothermic regional myocardial
ischemia. The model of antecedent ischemic myocardium
created by coronary artery occlusion was chosen not only to
simulate surgical revascularization of acutely ischemic
myocardium but also as a model of regionally jeopardized
myocardium vulnerable to ischemic and reperfusion inju-
ries. In this model, cariporide in blood cardioplegia used at
a concentration of 10 mol/L did not directly inhibit neu-
trophil activities but did reduce postischemic infarct size,
neutrophil accumulation, and tissue edema in the area at
risk. It also reduced coronary artery endothelial dysfunction.
This concentration of cariporide is higher than that used in
previous studies with isolated crystalloid-perfused hearts
(approximately 1 mol/L).
Treatment with cariporide-enhanced blood cardioplegia
Figure 2. Plasma CK activity during time course of experiment in
vehicle (Veh, squares) and cariporide (NHEI, circles) groups.
Base, Baseline; Isch, ischemia; R30, 30 minutes of reperfusion;
R60, 60 minutes of reperfusion; R90, 90 minutes of reperfusion;
R120, 120 minutes of reperfusion. Asterisk designates P value
versus vehicle group.
Figure 1. Area at risk relative to left ventricular mass (AAR/LV)
and infarct size as area of necrosis relative to area at risk
(An/AAR) in vehicle (Veh, black bars) and cariporide (NHEI, white
bars) groups. Asterisk designates P value versus vehicle group.
Muraki et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 1 161
CS
P
did not, however, improve functional recovery in the area at
risk. Although NHE inhibitors have been reported to be
more effective when hearts are treated before the onset of
ischemia (coronary artery occlusion) than after ischemia (at
reperfusion),14,15,32,33 this study clearly demonstrated that
NHE inhibitor administration in hypothermic cardioplegia
was cardioprotective, in agreement with other studies of
crystalloid18 or blood34 cardioplegic solutions. Previous
studies have shown that the NHE mechanism remains func-
tional even under hypothermic conditions31 and is therefore
a potential target for inhibition when hypothermic condi-
tions are used. Although cariporide attenuates neutrophil
activities at higher concentrations, consistent with reports
for other NHE inhibitors,35 the concentration used in this
study was below that which would directly inhibit neutro-
phil functions. Thus the cardioprotection was likely exerted
on the myocardium directly rather than by antineutrophil
mechanisms. In addition, there was no evidence that cari-
poride may have had a direct protective effect on the cor-
onary artery endothelium. Attenuation of postischemic en-
dothelial dysfunction may also have resulted from a
reduction in ischemic injury and a subsequent inflammatory
response to reperfusion involving the endothelium.
In the surgical setting used in this protocol, cariporide
had no opportunity to intervene during the period of coro-
nary occlusion. However, cariporide could intervene during
the ischemia imposed between infusions of cardioplegic
solution and could also reduce reperfusion injury. The de-
livery of blood cardioplegia to ischemic myocardium is, in
fact, a form of reperfusion. Maddaford and Pierce25 reported
that the NHE mechanism was most active during the initial
phase of reperfusion, and inhibition of the mechanism at
that time could thereby attenuate subsequent calcium over-
load.32 Calcium overload is a suspected mechanism of the
transition from reversible to irreversible injury. The reduc-
tion in neutrophil accumulation in the area at risk with
cariporide treatment is consistent with a generalized reduc-
tion in the inflammatory response to ischemia-reperfusion16
rather than with a direct antineutrophil effect. Numerous
studies have reported a correlation between attenuated neu-
trophil accumulation and reduced postischemic injury in
both surgical and nonsurgical models of ischemia-reperfu-
sion.16
Previous studies have demonstrated that NHE-1 is the
sole isoform detectable in the cardiac myocyte36 and that the
activity of the NHE is responsible for approximately 50% of
extrusion of hydrogen ion equivalents in cardiac tissue.37
Cariporide inhibits more than 95% of the NHE-1 activity at
1 mol/L concentration. Inhibition of the NHE-1 mecha-
nism during myocardial ischemia and reperfusion delays
realkalinization to normal intracellular pH9,38 and prevents
subsequent calcium overload and its deleterious conse-
quences in cardiomyocytes.32,38 We did not measure intra-
cellular pH or intracellular calcium in this study, but we
speculate that the inhibition of calcium entry and accumu-
lation occurred primarily at the time of aortic crossclamping
and at reperfusion.
We found that recovery of postischemic segmental func-
tion was not significantly improved by cariporide, despite
dramatic reductions in infarct size and myocardial edema.
Segmental work at 90 and 120 minutes of reperfusion
strongly tended to be greater in the group treated with
cariporide blood cardioplegia, whereas there was no differ-
ence in segmental shortening. This suggests that there was
Figure 3. MPO activity in nonischemic (Non-Isc), nonnecrotic
(Non-Nec), and necrotic area at risk (AAR) postexperimental
myocardial tissue samples from vehicle (Veh, black bars) and
cariporide (NHEI, white bars) groups. Asterisk designates P value
versus vehicle group.
Figure 4. Myocardial water content after desiccation of suben-
docardial (Endo) and subepicardial (Epi) tissue samples in both
area at risk (AAR) and nonischemic (Non-Isc) zones at end of
experiment in vehicle (Veh, black bars) and cariporide (NHEI,
white bars) groups. Asterisk designates P value versus vehicle
group within each area of myocardium.
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still systolic bulging in the ischemic-reperfused myocar-
dium, but shortening occurred during late systole. This
failure to restore contractile function was also reported for
previous studies in which the NHE inhibitor was adminis-
tered after the onset of coronary occlusion.14,15,39 However,
models of global ischemia have reported salutary effects.
Reversible global ischemia may involve myocardial stun-
ning, as opposed to the infarction observed with more
prolonged periods of regional occlusion. However, it is not
clear whether long-term recovery would demonstrate bene-
fit, because most studies were conducted in acute (hours of
reperfusion) models.
In summary, the present study demonstrated that blood
cardioplegia supplemented with the NHE inhibitor caripo-
ride provided superior cardioprotection following normo-
thermic regional myocardial ischemia when used as an
adjunct to blood cardioplegia. The protective effect was
likely exerted directly on the myocytes since the concentra-
tion used was less than concentrations that directly inhibit
neutrophil function. However, the attenuation of neutrophil
accumulation and endothelial dysfunction most likely rep-
resent a reduced inflammatory response to ischemia-reper-
fusion. The effectiveness of hypothermic blood cardioplegia
supplemented with such purported cardioprotective agents
is predicated on the ability of the agent of interest to exert
its therapeutic effects during the cardioplegic period or
thereafter on the end points measured. In previous clinical
trials of NHE inhibitors, such as the GUARDIAN Trial,20
cariporide was administered intravenously to high-risk pa-
tients before cardiac surgery and for as long as several days
perioperatively. However, the greatest risk for the patient
occurs in the immediate postoperative period, the events of
which may be influenced by intraoperative events and the
adequacy of myocardial protection. Incorporation of a NHE
inhibitor only at the time of cardioplegia delivery is a
strategy that has not been tested yet in clinical trials. This
study provides a scientific foundation supporting the use of
NHE inhibitors during the intraoperative period as an ad-
junct to clinical cardioplegia. However, it is not known
whether continued postischemic administration would have
resulted in further cardioprotection. In addition, further
studies should be pursued to determine whether use of a
higher concentration of cariporide to directly inhibit neu-
trophil superoxide radical generation would increase the
degree of myocardial protection.
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Figure 5. Vasorelaxation responses to incremental concentrations of acetylcholine (left) and sodium nitroprusside
(right) in both occluded-reperfused LAD (squares) and nonischemic LCx (circles) coronary artery rings. A, Vehicle
(Veh) group. B, Cariporide (NHEI) group. Asterisk designates P value versus vehicle group at same concentration.
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